Przejdź do zawartości
Merck

Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2.

Neurochemical research (2017-04-07)
Cameron S Metcalf, Misty D Smith, Brian D Klein, Daniel R McDougle, Liuyin Zhang, Grzegorz Bulaj
ABSTRAKT

The potential clinical utility of galanin peptidic analogs has been hindered by poor metabolic stability, lack of brain penetration, and hyperglycemia. In addition to possessing potent anticonvulsant efficacy, galanin analogs are analgesic in various assays. The purpose of these studies was to evaluate the lead galanin receptor type 2 (GalR2)-preferring analog, NAX 810-2, in various pain assays, as well as determine any potential for insulin inhibition, growth hormone stimulation, and cognitive impairment. NAX 810-2 was evaluated in mouse (carrageenan, formalin, tail flick, plantar incision) and rat pain models (partial sciatic nerve ligation). NAX 810-2 dose-dependently increased paw withdrawal latency following plantar administration of carrageenan (ED

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Human GH ELISA Kit, for serum, plasma, cell culture supernatant and urine